Curanex Pharmaceuticals (CURX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

CURX · Stock Price

USD 0.32-0.14 (-31.00%)

Market Cap: $9.2M

Historical price data

Market Cap: $9.2MFounded: 2020Employees: 1-10HQ: New York, United States

Sector Ranking#345 in Small Molecule Drugs

Overview

Curanex Pharmaceuticals, founded in 2020, is a pre-revenue, micro-cap public company with a mission to create a healthier world by unlocking the therapeutic potential of phytomedicine through rigorous scientific validation. The company's core strategy involves applying advanced analytical chemistry and modern pharmaceutical R&D to systematically develop novel small molecule drugs from Traditional Chinese Medicine (TCM) compounds. While its specific pipeline remains undisclosed, Curanex has assembled a leadership team and scientific advisory board with deep, relevant expertise in drug development, TCM research, and competitive intelligence to execute on this unique approach.

Inflammatory DiseasesAutoimmune DiseasesInfectious DiseasesOncologyMetabolic Disorders

Technology Platform

An integrated platform that applies advanced analytical chemistry and modern drug development processes to systematically identify, isolate, and develop novel small molecule active pharmaceutical ingredients (APIs) from validated Traditional Chinese Medicine (TCM) phytomedicinal sources.

Funding History

1

Total raised:$5M

Seed$5MUndisclosedSep 15, 2021

Opportunities

Curanex's approach taps into the vast, pre-validated chemical library of Traditional Chinese Medicine, potentially de-risking early-stage discovery and unlocking novel mechanisms of action for complex diseases.

Successful development could lead to valuable partnerships with larger pharma companies seeking to replenish pipelines with innovative small molecules.

Risk Factors

The company is at a very early, pre-pipeline stage with no disclosed drug candidates, facing high scientific risk in translating traditional knowledge into modern drugs.

Its micro-cap, pre-revenue status creates severe financial risk and dependency on future dilutive capital raises to fund operations and R&D.

Competitive Landscape

Curanex competes with large pharma natural product programs, Chinese biotechs modernizing TCM (e.g., Chi-Med), and botanical drug developers. Its key differentiator is the integrated team combining deep TCM academic expertise with proven Western pharmaceutical development and regulatory experience.